Glancy Prongay & Murray & Paragon Therapeutics
2 shared events · Importance 3 · Last updated Sep 09, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Glancy Prongay & Murray: Filed a class action lawsuit against Capricor.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
Regulatory
Glancy Prongay & Murray: The firm announced the opportunity for investors with losses to lead the securities fraud class action before the September 28, 2026 deadline.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
100
Glancy Prongay & Murray filed class action Paragon TherapeuticsCapricor Deramiocel...
80
Glancy Prongay & Murray filed class action Paragon TherapeuticsCapricor Deramiocel...
70
Glancy Prongay & Murray commenced investigation Paragon TherapeuticsCapricor Deramiocel...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Glancy Prongay & Murray and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard